Atossa Genetics Net Income
| ATOS Stock | USD 4.15 0.05 1.19% |
As of the 17th of February 2026, Atossa Genetics shows the Mean Deviation of 4.15, risk adjusted performance of (0.17), and Standard Deviation of 6.46. Atossa Genetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atossa Genetics variance and potential upside to decide if Atossa Genetics is priced correctly, providing market reflects its regular price of 4.15 per share. Given that Atossa Genetics has information ratio of (0.23), we suggest you to validate Atossa Genetics's prevailing market performance to make sure the company can sustain itself at a future point.
Atossa Genetics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Atossa Genetics' valuation are provided below:Atossa Genetics does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Is there potential for Health Care Equipment & Supplies market expansion? Will Atossa introduce new products? Factors like these will boost the valuation of Atossa Genetics. If investors know Atossa will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Atossa Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Atossa Genetics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Atossa Genetics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Atossa Genetics' market price to deviate significantly from intrinsic value.
Understanding that Atossa Genetics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Atossa Genetics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Atossa Genetics' market price signifies the transaction level at which participants voluntarily complete trades.
Atossa Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Atossa Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Atossa Genetics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Atossa Genetics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Atossa Genetics or generate 0.0% return on investment in Atossa Genetics over 90 days. Atossa Genetics is related to or competes with Oncolytics Biotech, Tevogen Bio, Greenwich Lifesciences, Instil Bio, Immix Biopharma, Whitehawk Therapeutics, and Clene. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medic... More
Atossa Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Atossa Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Atossa Genetics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.23) | |||
| Maximum Drawdown | 42.59 | |||
| Value At Risk | (9.93) | |||
| Potential Upside | 6.75 |
Atossa Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Atossa Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Atossa Genetics' standard deviation. In reality, there are many statistical measures that can use Atossa Genetics historical prices to predict the future Atossa Genetics' volatility.| Risk Adjusted Performance | (0.17) | |||
| Jensen Alpha | (1.44) | |||
| Total Risk Alpha | (1.77) | |||
| Treynor Ratio | (2.90) |
Atossa Genetics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.17) | |||
| Market Risk Adjusted Performance | (2.89) | |||
| Mean Deviation | 4.15 | |||
| Coefficient Of Variation | (457.41) | |||
| Standard Deviation | 6.46 | |||
| Variance | 41.67 | |||
| Information Ratio | (0.23) | |||
| Jensen Alpha | (1.44) | |||
| Total Risk Alpha | (1.77) | |||
| Treynor Ratio | (2.90) | |||
| Maximum Drawdown | 42.59 | |||
| Value At Risk | (9.93) | |||
| Potential Upside | 6.75 | |||
| Skewness | (2.28) | |||
| Kurtosis | 10.2 |
Atossa Genetics Backtested Returns
Atossa Genetics secures Sharpe Ratio (or Efficiency) of -0.22, which signifies that the company had a -0.22 % return per unit of risk over the last 3 months. Atossa Genetics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Atossa Genetics' Mean Deviation of 4.15, standard deviation of 6.46, and Risk Adjusted Performance of (0.17) to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Atossa Genetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Atossa Genetics is expected to be smaller as well. At this point, Atossa Genetics has a negative expected return of -1.41%. Please make sure to confirm Atossa Genetics' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Atossa Genetics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.83 |
Very good predictability
Atossa Genetics has very good predictability. Overlapping area represents the amount of predictability between Atossa Genetics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Atossa Genetics price movement. The serial correlation of 0.83 indicates that around 83.0% of current Atossa Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.83 | |
| Spearman Rank Test | 0.78 | |
| Residual Average | 0.0 | |
| Price Variance | 5.25 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Atossa Genetics reported net income of (25.5 Million). This is 107.47% lower than that of the Health Care Equipment & Supplies sector and 136.41% lower than that of the Health Care industry. The net income for all United States stocks is 104.47% higher than that of the company.
Atossa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Atossa Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Atossa Genetics could also be used in its relative valuation, which is a method of valuing Atossa Genetics by comparing valuation metrics of similar companies.Atossa Genetics is currently under evaluation in net income category among its peers.
Atossa Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (15.85 M) | ||||
| Shares Outstanding | 8.61 M | ||||
| Shares Owned By Insiders | 0.32 % | ||||
| Shares Owned By Institutions | 20.41 % | ||||
| Number Of Shares Shorted | 4.7 M | ||||
| Price To Earning | (0.62) X | ||||
| Price To Book | 0.72 X | ||||
| EBITDA | (27.6 M) | ||||
| Net Income | (25.5 M) | ||||
| Cash And Equivalents | 125.54 M | ||||
| Cash Per Share | 0.99 X | ||||
| Total Debt | 4.97 M | ||||
| Current Ratio | 35.19 X | ||||
| Book Value Per Share | 5.78 X | ||||
| Cash Flow From Operations | (21.03 M) | ||||
| Short Ratio | 2.17 X | ||||
| Earnings Per Share | (3.47) X | ||||
| Target Price | 68.75 | ||||
| Number Of Employees | 15 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 36.17 M | ||||
| Total Asset | 76.44 M | ||||
| Retained Earnings | (211.79 M) | ||||
| Working Capital | 69.49 M | ||||
| Current Asset | 4.29 M | ||||
| Current Liabilities | 2.5 M | ||||
| Net Asset | 76.44 M |
About Atossa Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Atossa Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Atossa Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Atossa Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.